. Nihconsensus, Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy, JAMA, vol.285, pp.785-795, 2001.

, WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report. Brussels: World Health Organization, 2004.

D. Bliuc, Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women, JAMA, vol.301, pp.513-521, 2009.

K. Briot, M. Maravic, and C. Roux, Changes in number and incidence of hip fractures over 12 years in France, Bone, vol.81, pp.131-137, 2015.

K. Briot, update of French recommendations on the management of postmenopausal osteoporosis, Jt. Bone Spine Rev. Rhum, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01808094

J. A. Kanis, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA, vol.24, pp.23-57, 2013.

G. A. Wells, Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst. Rev. CD001155, 2008.

G. Wells, Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst. Rev, vol.004523, 2008.

G. A. Wells, Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst. Rev, vol.003376, 2008.

S. Epstein, Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety, Maturitas, vol.54, pp.1-10, 2006.

I. Imaz, Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA, vol.21, p.7446, 2010.

S. Ross, A meta-analysis of osteoporotic fracture risk with medication nonadherence, Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res, vol.14, pp.571-581, 2011.

M. Hiligsmann, V. Rabenda, O. Bruyère, and J. Reginster, The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients, Health Policy Amst. Neth, vol.96, pp.170-177, 2010.

B. Vrijens, A new taxonomy for describing and defining adherence to medications, Br. J. Clin. Pharmacol, vol.73, pp.691-705, 2012.

, Arrêté du 4 mai 2012 portant approbation de la convention nationale organisant les rapports entre les pharmaciens titulaires d' officine et l' assurance maladie

, European Medicins Agency. Guideline on the investigation of bioequivalence, 2010.

M. Shakweh, I. Bravo-osuna, and G. Ponchel, Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci, vol.31, pp.262-270, 2007.

W. P. Olszynski, J. D. Adachi, and K. S. Davison, Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates, J. Osteoporos, p.420451, 2014.

J. P. Brown, K. S. Davison, W. P. Olszynski, K. A. Beattie, and J. D. Adachi, A critical review of brand and generic alendronate for the treatment of osteoporosis, SpringerPlus, vol.2, p.550, 2013.

J. D. Ringe and G. Möller, Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis, Rheumatol. Int, vol.30, pp.213-221, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00568290

O. Ström and E. Landfeldt, The association between automatic generic substitution and treatment persistence with oral bisphosphonates, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA, vol.23, pp.2201-2209, 2012.

O. Sheehy, C. M. Kindundu, M. Barbeau, and J. Lelorier, Differences in persistence among different weekly oral bisphosphonate medications, Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA, vol.20, pp.1369-1376, 2009.

J. F. Van-boven, P. T. De-boer, M. J. Postma, and S. Vegter, Persistence with osteoporosis medication among newly-treated osteoporotic patients, J. Bone Miner. Metab, vol.31, p.570, 2013.

H. Halkin, Brand versus generic alendronate: gastrointestinal effects measured by resource utilization, Ann. Pharmacother, vol.41, pp.29-34, 2007.

W. Buono and E. , Coming full circle in the measurement of medication adherence: opportunities and implications for health care, Patient Prefer. Adherence, vol.11, pp.1009-1017, 2017.

S. De-geest, ESPACOMP Medication Adherence Reporting Guideline (EMERGE), Ann. Intern. Med, vol.169, pp.30-35, 2018.

P. Tuppin, L. De-roquefeuil, A. Weill, P. Ricordeau, and Y. Merlière, French national health insurance information system and the permanent beneficiaries sample, Rev. DÉpidémiologie Santé Publique, vol.58, pp.286-290, 2010.

P. Latry, M. Molimard, B. Bégaud, and K. Martin-latry, How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database, Eur. J. Clin. Pharmacol, vol.66, pp.743-748, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00589490

K. Martin-latry and B. Bégaud, Pharmacoepidemiological research using French reimbursement databases: yes we can!, Pharmacoepidemiol. Drug Saf, vol.19, pp.256-265, 2010.

W. M. Vollmer, Comparison of pharmacy-based measures of medication adherence, BMC Health Serv. Res, vol.12, p.155, 2012.

A. Palmaro, G. Moulis, F. Despas, J. Dupouy, and M. Lapeyre-mestre, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam. Clin. Pharmacol, vol.30, pp.616-624, 2016.

P. Noize, Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study, Pharmacoepidemiol. Drug Saf, vol.18, pp.310-319, 2009.

S. Sinnott, J. M. Polinski, S. Byrne, and J. J. Gagne, Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class, J. Clin. Epidemiol, vol.69, pp.107-113, 2016.

S. M. Langan, The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE), BMJ, vol.363, p.3532, 2018.

J. Bezin, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol. Drug Saf, vol.26, pp.954-962, 2017.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J. Chronic Dis, vol.40, pp.373-383, 1987.

A. Bannay, The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, Med. Care, vol.54, pp.188-194, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

P. Caillet, Algorithms for the identification of hospital stays due to osteoporotic femoral neck fractures in European medical administrative databases using ICD-10 codes: A non-systematic review of the literature, Rev. Epidemiol. Sante Publique, vol.65, pp.198-208, 2017.

W. Index,

P. C. Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational, Studies. Multivar. Behav. Res, vol.46, pp.399-424, 2011.

S. Xu, Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health, J. Int. Soc. Pharmacoeconomics Outcomes Res, vol.13, pp.273-277, 2010.

P. C. Austin, Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples, Stat. Med, vol.28, pp.3083-3107, 2009.